Home/Alex Hope

Ros Deegan – BioLeader Interview

Ros Deegan BioLeaders Interview – Ros Deegan (October 2019) CEO OMass Therapeutics in Oxford. Has lived in Belgium, France, US and UK. Studied at Cambridge University and INSEAD. Likes to explore both the physical world with her husband, and the scientific world with her company. Key milestones in your career journey to date? Moving into the biotech world in 2008, travelling between countries – working in the US in 1999 and again 2006 – 2019; first SVP role and IPO at Trevena in 2013/14; first CEO role at OMass in 2019. Who has had the greatest influence over your [...]

By |16 October 2019|Categories: BioLeaders|0 Comments

David Roblin – BioLeader Interview

David Roblin BioLeaders Interview – David Roblin (October 2019) President of R&D and COO of Summit Therapeutics PLC, Chair of Scientific Translation at The Crick, NED at SoseiHeptares PLC, various grant committees at Wellcome and LEO Foundation; age 53; married with 3 children; Welshman of Kent; education: comprehensively near Swansea, then UCL and St George’s; Hobbies: travelling extensively with my family – Namibia in 2019. Key milestones in your career journey to date? Leaving the land of my fathers (Wales) in 1985; meeting my wife, Sally, at medical school in 1987; my career went from bedside to bench and [...]

By |03 October 2019|Categories: BioLeaders|0 Comments

IR35 in a Period of Transition as April 2020 Fast Approaches

The following is a collaborative piece, produced with our financial partners Price Bailey. What is IR35 in a nutshell? IR35 was first introduced in 2000, and is designed to reduce tax avoidance by contractors who HMRC believe to be ‘disguised employees’ – people who work in a similar way to full-time employees but then bill for their services via their limited companies to make their business as tax efficient as possible.  Originally, IR35 employment status was declared by the contractor and not the hiring organisation. But in 2017, the rules changed significantly for the public sector, with the onus to [...]

By |04 September 2019|Categories: News|0 Comments

PIR Set to Attend BIA Women in Biotech Evening

This September BIA are taking their successful Women in Biotech series to Cambridge, where they look forward to engaging with attendees to inspire more people to tackle diversity challenges within their organisations. There will be some excellent speakers for a panel discussion, chaired by Sally Shorthose, which will focus on diversity challenges and how to address them in the working environment. Carolyn Douthwaite (Founder & NED), Sally Hope (Managing Partner), Jayne Fergusson (Projects Director), Sarah Lloyd (Client Partner Interims) and Gemma Adamante (Senior Executive Researcher) from PIR International will all be in attendance. If you see one of the [...]

By |08 August 2019|Categories: News|0 Comments

PIR Announces International Expansion with Appointment of Globally Recognised Talent

PIR is delighted to announce the appointment of highly regarded executives to support its planned international expansion.  From today, PIR life sciences executive search and interim management will be joined by Tom Bradley and Stuart Penney as Senior Partners, Gemma Adamante as Senior Executive Researcher and George Owen as Executive Researcher.  These valuable additions to an already strong team will fuel the PIR drive to expand internationally within the life sciences sector.  Tom spent over ten years at Pfizer before moving into global executive search where he works across the Pharmaceutical, Biotech and Consumer Health sectors, hiring senior leaders across [...]

By |03 June 2019|Categories: News|0 Comments

PIR Strengthens its Advisory Board

PIR, a leading executive search company based near Cambridge, UK, which identifies senior talent for early stage life science Boards, is delighted to confirm the appointment of two senior Advisors to their Board. Maureen Coleman joins as Chair Mentor and Mark Treherne as Associate Consultant. Maureen and Mark are hugely respected by the sector for their success in building early stage, investor backed, life science companies; through to trade sale or transition onto the public markets. Their networks with investors, government and business leaders in the sector are exceptional. Carolyn Douthwaite, Founder of PIR commented: “We are thrilled that Maureen [...]

By |05 September 2018|Categories: News|0 Comments
Go to Top